Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252290 · ClinicalTrials.gov registry record · Phase 2
Breast Cancer Risk Biomarkers in Postmenopausal Women
A Phase 2 study, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01252290: Completed Phase 2 study, sponsored by Carol Fabian, MD.
NCT01252290 is a Phase 2 study that has completed, run by Carol Fabian, MD. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01252290, a Phase 2 study, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
Primary Outcome
To determine the feasibility of an intervention of Lovaza™ 4 grams per day (\~ 1800 mg EPA and 1500 mg DHA) administered for 6 months to post-menopausal women under the age of 50.
Interventions
- DRUG Lovaza™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01252290 record still lists
NCT01252290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Lovaza™ is the first listed.
NCT01252290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01252290 about?
NCT01252290 is a clinical study titled "Breast Cancer Risk Biomarkers in Postmenopausal Women". This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer. This drug is currently approved by the FDA for reducing blood levels of triglycerides.
What is the current status of trial NCT01252290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2010-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01252290?
The interventions under investigation include: Lovaza™ (DRUG).
Who is sponsoring clinical trial NCT01252290?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01252290's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia